Stem Cells

<p>TNIK-IN-5: strong TNIK inhibitor (IC50=0.05μM), halts Wnt signaling, effective against colorectal cancer in vitro.</p>

<p>Sonidegib diphosphate (LDE225 diphosphate) is a selective antagonist of Smo that inhibits murine Smo and human Smo.Cost-effective and quality-assured.</p>

<p>Silmitasertib sodium salt (CX-4945 sodium salt) is a potent and orally bioavailable, highly selective inhibitor of CK2(IC50 of 1 nM, CK2α).</p>

<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>

<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>

<p>E2012 is a γ-secretase modulator (GSM).</p>

<p>Cyanoacetohydrazide (Cyanoacetic hydrazide) is an anti-TB drug. It has also been used to derive compounds that may have antitumor properties.</p>

<p>IK-930 is an orally active TEAD inhibitor (EC50 &lt; 0.1 µM) with potent potency.</p>

<p>CCT251545 is an potent and oral-bioavailable WNT signaling inhibitor(IC50 of 5 nM in 7dF3 cells).</p>

<p>Orally active GSK-3 inhibitor 4 targets GSK-3α/β, CDK2/5 (IC50: 0.45-0.68 μM) and may aid in Alzheimer's research by lowering Tau protein.</p>

<p>BML-286 is a WNT pathway modulator with potential anticancer activity and induces β-catenin- and TCF- dependent transcriptional activity.</p>

<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>

<p>Netarsudil Dihydrochloride (AR-13324 Dihydrochloride) is an inhibitor of Rho-related protein kinase (ROCK) and norepinephrine transporter (NET) and is effective in reducing intraocular pressure (IOP).Cost-effective and quality-assured.</p>

<p>Garetosmab (REGN 2477), a human IgG4 monoclonal antibody, inhibits activin A for potential cancer treatment and FOP study.</p>

<p>NGP555 is a modulator of γ-secretase.</p>

<p>Nefopam hydrochloride (Nefopam HCl) is the hydrochloride salt form of nefopam, a centrally-acting, non-opioid benzoxazocine with analgesic activity.</p>

<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: &gt;14.7, &gt;30 μM).</p>

<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>

<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>

<p>NMS-P715 is a highly selective and ATP-competitive MPS1 inhibitor(IC50 of 182 nM).</p>

<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>

<p>JW74 antagonizes LiCl-induced activation of the canonical Wnt signaling (IC50: 420 nM).</p>

<p>KY1220 destabilizes both β-catenin and Ras by targeting the Wnt/β-catenin pathway. It has an IC50 of 2.1 μM in HEK293 reporter cells.</p>

<p>CWP232228 is a selective Wnt/β-catenin pathway inhibitor targeting β-catenin/TCF binding, halting breast/liver CSC growth and metastasis safely.</p>

<p>MRT-83 is a potent Smo antagonist.</p>

<p>BRD0705: potent, selective GSK3α inhibitor, oral, IC50: 66 nM, 8x more selective than GSK3β.</p>

<p>Ponsegromab (PF 06946860), a humanized anti-GDF15 antibody, may treat cancer cachexia by blocking GDF15/GFRAL signaling.</p>

<p>ROCK inhibitor-2 is a selective dual inhibitor of ROCK1 and ROCK2 (IC50s of 17 nM and 2 nM, respectively).</p>

<p>ROCK2-IN-9 (compound 7u), a selective ROCK2 inhibitor with an IC50 value of 36.8 nM, demonstrates anticancer properties by impeding cancer cell migration and invasion. This action is achieved through the regulation of various actin cytoskeleton cellular activities. It holds potential for use in breast cancer research.</p>

<p>1(R),2(S)-epoxy Cannabidiol (Compound 2a) is a structural analog of phytocannabinoids, exhibiting significant inhibitory activity on the Wnt/β-catenin pathway. It holds potential for research as a neuroprotective agent.</p>

<p>MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.</p>

<p>YAP/TAZ Inhibitor-4 (Compound 45) acts as an inhibitor of YAP/TAZ, exhibiting inhibitory activity on TEAD transcriptional activation by preventing the interaction between YAP or TAZ and TEAD.</p>

<p>CSNK2-IN-2 (compound 2) is an orally active inhibitor of CSNK2. It is utilized in antiviral research.</p>

<p>MSC-1254 is a reversible, selective, and covalent inhibitor of TEAD1, primarily utilized in cancer research.</p>

<p>Disitertide acetate: a TGF-β1 and PI3K blocker, promotes apoptosis; inhibits receptor interaction.</p>

<p>MSC-5046 is a selective inhibitor of TEAD1.</p>

<p>Casein kinase 1δ-IN-7 is a Casein kinase 1δ inhibitor for neurodegenerative diseases such as Alzheimer's disease.</p>

<p>ALK5-IN-83 (compound 13b) is an ALK5 inhibitor with an IC50 of 0.13 μM. It suppresses TGF-β1-induced Smad2 phosphorylation and cell motility in A549 cells.</p>

<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>

<p>Ripasudil free base (K-115 (free base)) is a selective and potent ROCK inhibitor, is a novel and potent antiglaucoma agent.</p>

<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>

<p>Emugrobart is a humanized IgG1κ antibody targeted at GDF8, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>

<p>STAT3HiBiT degrader 1 is a potent degrader of STAT3HiBiT, exhibiting a DC50 of less than 0.05 μM in A549 cells.</p>

<p>Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and is an effective Wnt agonist.</p>

<p>Linavonkibart (SRK181) is a humanized antibody targeting TGFβ1 that blocks the release of TGF-β1 protein by specifically binding latent TGF-β1.</p>

<p>CCT 031374 hydrobromide is a TCF/β-catenin inhibitor with antitumor activities.</p>

<p>WAY-656935 inhibits ROCK.</p>

<p>Foxy-5 Ammonium Salt, a WNT5A mimetic, blocks epithelial cancer cell migration without β-catenin impact and curbs prostate cancer spread.</p>

<p>YAP-TEAD-IN-1 acetate is an effective and competitive inhibitor of YAP–TEAD interaction with an IC50 of 25 nM.</p>

<p>MR24 is a derivative of G-5555 and acts as an inhibitor of mammalian STE20-like (MST) kinases. It selectively targets MST3 and MST4, with EC50 values of 57 nM and 583 nM, respectively.</p>

<p>STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM.</p>

<p>Casein kinase 1δ-IN-8 is an inhibitor of casein kinase 1δ and is used to treat neurodegenerative diseases such as Alzheimer's disease type.</p>

<p>YAP/TEAD-IN-1 (compound 4) is a potent inhibitor of YAP and TEAD, exhibiting antioxidant properties. It demonstrates antiproliferative effects on tumor cells while showing minimal cytotoxic activity towards normal human cells.</p>

<p>LP-922056 is an inhibitor of Notum Pectinacetylesterase with EC50 values of 21 nM, 55 nM for human and mouse, respectively.</p>

<p>BAY 593 functions as an inhibitor of geranylgeranyltransferase-I (GGTase-I), effectively preventing the activation of Rho-GTPases and consequently inactivating YAP1/TAZ signaling pathways. It has been shown to inhibit tumor growth dose-dependently in xenograft mouse models, exhibiting IC50 values of 38.4 nM in MT-1080 cells and 564 nM in MDA-MB-231 cells, as well as in PXF 541 xenografts.</p>

<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>

<p>Wnt/β-catenin agonist 3 is a Wnt/beta-catenin agonist.</p>

<p>Sotatercept (ACE-011) is an ActRIIA-Fc fusion protein and an inhibitor of activin signaling.</p>

<p>2H-1-Benzopyran-3-carboxamide, N-[4-(4-ethyl-1-piperazinyl)phenyl]-2-oxo- is a compound that is potential for the treatment of tumours.</p>

<p>RhoA-ROCK-IN-1 (Compound b19) is an inhibitor of the RhoA/ROCK pathway. It significantly inhibits cell proliferation, migration, and invasion, while promoting cell apoptosis (apoptosis). RhoA-ROCK-IN-1 exhibits strong anticancer activities by inhibiting the RhoA/ROCK pathway.</p>

<p>LX-7101 hydrochloride is a potent LIMK and ROCK2 inhibitor with antihypertensive activity, inhibits LIMK1/2, ROCK, PKA, and can be used to study glaucoma.</p>

<p>GSK3-IN-4 is a GSK-3 inhibitor with IC50 of 0.101-1 μM of GSK-3α and GSK-3β in Calipe Assay.</p>

<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>

<p>Tubastatin inhibits TGF-β1-induced S6K phosphorylation, HIF-1α expression and VEG F expression.</p>

<p>Plant 14-3-3-IN-1 (Compound 2) is an inhibitor of the Arabidopsis thaliana 14-3-3 protein, with an IC50 of 1.21 μM. It exhibits varying inhibitory activity against different 14-3-3 isoforms and promotes the closure of leaf stomata.</p>

<p>(R)-Lisofylline ((R)-Lisophylline) is an inhibitor of lysophosphatidic acid acyltransferase (IC50 = 0.6 µM).</p>

<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>

<p>GSK3-IN-1 is a GSK3B-glycogen synthase kinase-3 beta inhibitor.</p>

<p>YAP-TEAD-IN-3 inhibitor YAP/TAZ-TEAD interactions Avi-human TEAD (4217-434) YAP-TEAD-IN-3 inhibits YAP reporter gene expression and NCI-H2052 cell proliferation</p>

<p>GSK-3β Inhibitor 19 (compound 36) is an inhibitor of GSK-3β with an IC50 value of 70 nM. It is applicable in research related to anti-inflammatory and Alzheimer's disease.</p>

<p>STAT3-IN-34 (Compound 15E) acts as a STAT3 inhibitor, blocking both the nuclear translocation and the transcriptional regulator activity of STAT3. It effectively inhibits HaCaT cell proliferation with an IC50 value of 0.008 μM. Additionally, STAT3-IN-34 reduces IL-17A expression and mitigates Imiquimod-induced psoriasis in mouse models.</p>

<p>Super-TDU (1-31) TFA, a peptide, inhibits YAP-TEAD; it has strong anti-tumor effects in gastric cancer models.</p>

<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>

<p>PROTAC YAP degrader-1, a targeted proteolysis promoting chimeric molecule, both degrades the YAP protein and inhibits its nuclear localization. This compound is formulated with Demethyl-NSC682769 as the target protein ligand, and utilizes (R,S,R)-AHPC-PEG2-C2-boc, which is the E3 ubiquitin ligase ligand + Linker conjugate. The linker incorporated in the design is Acid-PEG2-C2-Boc.</p>

<p>HC-258 is a direct TEAD inhibitor covalent Cys380, and reduces the transcriptional levels and inhibits the migration of CTGF, CYR61, AXL and NF2 MDA-MB-231.</p>

<p>Cirevetmab (ZTS-00521426), a caninized monoclonal antibody targeting Canis lupus familiaris TGFB1, is classified as an immunoglobulin G2-kappa.</p>

<p>Lerdelimumab (CAT-152) is an IgG4 monoclonal antibody targeting TGF-β2, used in glaucoma scarring research.</p>

<p>P17 Peptide, a human TGF-β1 inhibitory peptide, effectively blocks the activity of woodchuck TGF-β1.</p>

<p>CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.</p>

<p>TGFβRI-IN-7 (compound 16W) is a potent inhibitor of TGFβRI. It effectively inhibits the phosphorylation of SMAD2/3 and reduces the viability of H22 cells, with IC50 values of 12 nM and 65 nM, respectively. In an H22 cell xenograft model, TGFβRI-IN-7 exhibits antitumor efficacy with a TGI of 79.6%.</p>

<p>STAT3-IN-31 (compound K2071), derived from STATtic, acts as an inhibitor of both STAT3 and mitotic processes. This compound interrupts mitotic progression and impacts the formation of the mitotic spindle. Additionally, STAT3-IN-31 hampers migration in glioblastoma cells, suppresses cellular proliferation within tumor spheroids, induces senescence in glioblastoma, and inhibits the growth of Temozolomide-resistant cells while reducing the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein (MCP-1).</p>

<p>WAY-297174 is a human protein kinase CK2 inhibitor with IC50 of &gt; 33 μM.</p>

<p>TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of TEAD, showing inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% for TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at 10 μM. It exhibits strong antiproliferative and antimigratory effects on prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD-IN-19 holds potential for research in the field of cancer therapeutics.</p>

<p>Wnt pathway inhibitor 3 is a potent AC1 inhibitor with an IC50 value of 45 nM.Wnt pathway inhibitor 3 has antiproliferative activity and can be used in studies</p>

<p>Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.</p>

<p>NIBR-LTSi is a selective LATS kinase inhibitor that also activates YAP signaling, promotes tissue stem cell expansion and tissue regeneration in vitro/vivo.</p>

<p>ABC99 irreversibly inhibits wnt-deacylating enzyme NOTUM (IC50: 13 nM) with high serine hydrolase family selectivity.</p>

<p>GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.</p>

<p>CK1δ-IN-6: potent, selective CK-1δ inhibitor, IC50 23 nM, neuroprotective, anti-inflammatory, for neurodegenerative research.</p>

<p>TEAD-IN-16 (compound BC-011) is a potent inhibitor of TEAD, with an IC50 of 72.43 μM. This compound plays a significant role in cancer research.</p>

<p>A unique collection of 237 Wnt/Hedgehog/Notch signaling targeted compounds for high throughput and high content screening;</p>

<p>SLLK is a control peptide for LSKL.</p>

<p>Jagged-1 （188-204）is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin.</p>

<p>Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new</p>

<p>RBPJ Inhibitor-1 (RIN1), a compound that impedes the functional interaction between RBPJ and SHARP, effectively inhibits NOTCH-dependent tumor cell</p>

<p>YAP-IN-1 (Compound (+)-1) is an autophagy inhibitor specifically targeting YAP1. It binds to the Hippo pathway transcription factor YAP1 with a Kd of 9.13 μM, promoting its degradation through the chaperone-mediated autophagy (CMA) pathway. This process inhibits the Rab7-mediated fusion of autophagosomes with lysosomes and decreases autophagy levels without affecting lysosomal function. YAP-IN-1 shows potential for cancer research, including in hepatocellular carcinoma and breast cancer.</p>

<p>Fresolimumab (GC1008) is a human monoclonal antibody targeting active TGFβ1, TGFβ2, TGFβ3, studied for cancer and focal segmental glomerulosclerosis.</p>

<p>YW2036 is an inhibitor of Wnt signaling pathway.</p>

<p>Carboxylesterase-IN-2 is a potent Carboxylesterase Notum inhibitor (IC50 &lt;= 10 nM).Carboxylesterase-IN-2 has potential for the study of cancer diseases.</p>

<p>Casein kinase 1δ-IN-3 (Casein kinase 1δ-IN-3) (Compound 23a) is a casein kinase 1 delta (CK1d) inhibitor with a pIC50 of 6.5376 M.</p>